Third-Line Treatment Options for Metastatic Colorectal Cancer - Episode 4

Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

,

Panelists discuss their perspectives on the SUNLIGHT trial and how its active-arm comparator design, compared with placebo-controlled trials like FRESCO-2 and CORRECT, influences their treatment approach, while also exploring how specific efficacy outcomes impact their decision-making in third-line metastatic colorectal cancer.

EP. 1: Navigating mCRC: Treatment Options in the Third-Line Setting
EP. 2: Nuances With Defining “Refractory” mCRC in the Third-Line Setting
EP. 3: Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients
Now Viewing
EP. 4: Perspectives on the SUNLIGHT Trial: Study Design and Outcomes
EP. 5: Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection
EP. 6: Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab
EP. 7: Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment
EP. 8: Unmet Needs in Third-Line mCRC: Challenges and Opportunities
  1. What are your perspectives regarding the SUNLIGHT trial?
    1. Does this trial design with an active-arm comparator arm compared with trials utilizing a placebo-controlled comparator (eg, FRESCO-2, CORRECT) impact or influence your treatment approach? If so, how
  2. Are there certain efficacy outcomes between these agents that have a greater influence or impact on your decision-making?

Related Content:

Third-Line Treatment Options for Metastatic Colorectal Cancer
Unmet Needs in Third-Line mCRC: Challenges and Opportunities
Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment
Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab